Bonding for Life: Covalent Inhibition in Drug Discovery
Event overview
Irreversibly binding a small molecule drug to an enzyme and permanently disabling its function is not a new concept in the treatment of human disease. Over 40 covalent modifier drugs have been approved for clinical use by the FDA. Despite this fact, resistance in the pharmaceutical industry due to concerns about safety and off-target binding has propagated the view that development of a covalent inhibitor is a high risk strategy.
In this webinar, we traced the history of covalent inhibition in the pharmaceutical industry, highlighting the successes (and the horror stories), the strategies employed and where this is leading us.
This webinar was presented by Dr John Studley, Scientific Update.
Sponsors
Interested in sponsoring an event?
If you are interested in Sponsoring this event we still have some great sponsorship opportunities available at the conference. See our sponsorship section on the advantages that sponsorship can bring to your business or contact Dr Claire Francis at [email protected]
Become a speaker at one of our events
Share your expertise with a global audience of industry professionals. Scientific Update is continually seeking thought leaders and industry innovators to speak at our renowned conferences and training courses.
Bonding for Life: Covalent Inhibition in Drug Discovery
Webinar recording
Please enter your email address to access this recording.
Download slides
Please enter your email address to access these slides.